As health plans grapple with the rapidly rising cost of oncology medications and a “buy and bill” system that does not work for physicians or for the plans, they are seeking new strategies for providing these life-saving drugs to their members and for freeing up oncology and hematology practices to focus solely on caring for patients, not managing a pharmacy.
CEP17 Breast Cancer Tumors Are More Likely to Respond to Anthracyclines
BARCELONA—Breast cancer patients with the chromosome enumeration probe 17 (CEP17) alpha satellite abnormality are more likely to have good outcomes from chemotherapy involving anthracycline antibiotics than women without the abnormality, according to new data released at the Seventh European Breast Cancer Conference.
President Obama guaranteed Americans that after health reform became law they could keep their insurance plans and their doctors. It’s clear that this promise cannot be kept. Insurers and physicians are already reshaping their businesses as a result of Mr. Obama’s plan.
In the first head-to-head comparison of targeted oral tyrosine kinase inhibitors as initial treatment for early-stage chronic myeloid leukemia (CML), molecular and cytogenetic remissions were more common with nilotinib compared with imatinib, the previous standard for treating early-stage CML, said Giuseppe Saglio, MD.
Results 241 - 249 of 249